Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Article in Clinical Cancer Research (January 2024)
The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.
Article in Clinical Cancer Research (January 2024)
Article in Frontiers in Oncology (August 2023)
Article in Cancer Treatment Reviews (December 2022)